Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NCP112 in Healthy Subjects
NCT06263998Phase 1Recruiting
- Sponsor
- Huons
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NCP112 in dry eye syndrome (DED) (12 arms), sponsored by Huons. Primary endpoints: Eye irritation (Likert scale), Eye redness (Likert scale) and 4 more. Started Jul 2024; status: recruiting.
02
Drugs
NCP112
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT06263998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263998.